Biolidics: To Collaborate With A*STAR's Genome Institute Of Singapore To Develop New Liquid Biopsy Test For The Monitoring Of Breast Cancer Recurrence.10 Sep 2019 17:58
The recurrence of breast cancer has been the leading cause of death for breast cancer survivors. Combining the technology capabilities of both parties, this collaboration aims to co-develop a new and innovative liquid biopsy test, using the merits of CTCs and other circulating biomarkers, to predict the risk of breast cancer relapse. Breast cancer is currently the most common type of cancer in women and with the rising incidence of breast cancer, the global cancer diagnostic market for breast cancer may surpass US$2 billion in revenue by 2022...
Source: ShareInvestor Express